Spineway- US 2023 NASS Conference: VEOS System

VEOS system well received at the NASS 2023 conference
in the United States

Sales growth in France

Ecully, November 2, 2023 – Spineway Group, specialist in innovative implants for the treatment of serious spinal pathologies, is pleased to announce that its VEOS posterior spinal fixation system received an excellent response from the spinal implant industry at the North American Spine Society (NASS) Congress in Los Angeles last year. October¹.

During the event, the Group received numerous expressions of interest for its VEOS restraint system, which has received 510(k) clearance from the Food and Drug Administration (FDA), and established contacts with potential US partners for its distribution in the USA This innovative platform offers spine surgeons a unique modularity, as the rational organization of the implant and instrument kits allows them to perform many different types of procedures with a single system, both in open and minimally invasive surgery (MIS).

As a reminder, the VEOS range is one of a number of Distimp² products that now represent a significant part of the Group’s turnover in France. In the first nine months of 2023, Distimp’s sales in France increased by 45% compared to 2022, mainly driven by the success of the VEOS range at a large number of French healthcare institutions, including several university hospitals.

This trend should continue if sales of the VEOS range start in Spain before the end of 2023.

Thanks to these first positive developments, Spineway will continue its development plans, which is a confirmation its goal to become an innovative player in France and internationally, leader in less invasive spine treatments.

Next events:
November 10, 2023: Extraordinary General Meeting

SPINEWAY ELIGIBLE FOR PEA-SME (Small and Medium Business Equity Savings Plans)
Find out all about Spineway at www.spineway.com

This press release has been drawn up in both English and French. In case of contradictions, the French version shall prevail.

Spineway designs, produces and sells innovative implants and surgical instruments for the treatment of serious spinal conditions.
Spineway has an international network of more than 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specialized in innovation), has received the OSEO Excellence Award since 2011 and the Deloitte Fast 50 Award (2011). Rhône Alpes INPI Patent Innovation Award (2013) – INPI Talent Award (2015).
ISIN: FR001400BVK2 – ALSPW

Contacts:

1 Press release dated October 19, 2023, NASS Congress October 18-20, 2023, Los Angeles, USA.
2 Company acquired in 2021